Sino Biopharmaceutical Future Growth
Future criteria checks 2/6
Sino Biopharmaceutical is forecast to grow earnings and revenue by 13.7% and 6.9% per annum respectively. EPS is expected to grow by 14.3% per annum. Return on equity is forecast to be 8.7% in 3 years.
Key information
13.7%
Earnings growth rate
14.3%
EPS growth rate
Pharmaceuticals earnings growth | 10.7% |
Revenue growth rate | 6.9% |
Future return on equity | 8.7% |
Analyst coverage | Good |
Last updated | 26 Jul 2024 |
Recent future growth updates
Recent updates
Are Investors Undervaluing Sino Biopharmaceutical Limited (HKG:1177) By 48%?
Jul 12Here's Why Sino Biopharmaceutical (HKG:1177) Can Manage Its Debt Responsibly
May 21Sino Biopharmaceutical Limited's (HKG:1177) 27% Cheaper Price Remains In Tune With Earnings
Apr 21What Does The Future Hold For Sino Biopharmaceutical Limited (HKG:1177)? These Analysts Have Been Cutting Their Estimates
Apr 03Sino Biopharmaceutical Limited's (HKG:1177) Intrinsic Value Is Potentially 34% Above Its Share Price
Mar 20Sino Biopharmaceutical Limited's (HKG:1177) Shares May Have Run Too Fast Too Soon
Dec 18Does Sino Biopharmaceutical (HKG:1177) Have A Healthy Balance Sheet?
Dec 02Sino Biopharmaceutical Limited (HKG:1177) Shares Could Be 41% Below Their Intrinsic Value Estimate
Nov 17We Think Sino Biopharmaceutical (HKG:1177) Can Manage Its Debt With Ease
Aug 30Is There An Opportunity With Sino Biopharmaceutical Limited's (HKG:1177) 50% Undervaluation?
May 26Sino Biopharmaceutical (HKG:1177) Has A Rock Solid Balance Sheet
Apr 20Is Sino Biopharmaceutical Limited (HKG:1177) Trading At A 38% Discount?
Feb 09Is There An Opportunity With Sino Biopharmaceutical Limited's (HKG:1177) 41% Undervaluation?
Nov 11Sino Biopharmaceutical (HKG:1177) Seems To Use Debt Quite Sensibly
Oct 24Is There An Opportunity With Sino Biopharmaceutical Limited's (HKG:1177) 46% Undervaluation?
Jul 08Is Sino Biopharmaceutical (HKG:1177) Using Too Much Debt?
Apr 28An Intrinsic Calculation For Sino Biopharmaceutical Limited (HKG:1177) Suggests It's 45% Undervalued
Jan 22Sino Biopharmaceutical (HKG:1177) Has A Pretty Healthy Balance Sheet
Dec 03Earnings and Revenue Growth Forecasts
Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
---|---|---|---|---|---|
12/31/2026 | 34,551 | 3,281 | 5,966 | 7,774 | 18 |
12/31/2025 | 32,133 | 3,060 | 4,812 | 6,602 | 24 |
12/31/2024 | 29,511 | 2,816 | 5,331 | 6,882 | 24 |
12/31/2023 | 26,199 | 1,847 | 4,591 | 6,066 | N/A |
6/30/2023 | 28,864 | 1,881 | 3,314 | 4,987 | N/A |
3/31/2023 | 28,822 | 2,212 | 4,017 | 5,626 | N/A |
12/31/2022 | 26,026 | 2,059 | 4,719 | 6,265 | N/A |
9/30/2022 | 28,241 | 5,296 | 4,895 | 6,622 | N/A |
6/30/2022 | 27,701 | 8,049 | 5,071 | 6,980 | N/A |
3/31/2022 | 27,215 | 13,655 | N/A | N/A | N/A |
12/31/2021 | 26,861 | 14,608 | 3,499 | 5,366 | N/A |
9/30/2021 | 26,129 | 12,465 | N/A | N/A | N/A |
6/30/2021 | 25,353 | 10,011 | 4,337 | 6,105 | N/A |
3/31/2021 | 24,668 | 3,809 | N/A | N/A | N/A |
12/31/2020 | 23,647 | 2,771 | 3,537 | 5,325 | N/A |
9/30/2020 | 23,039 | 2,302 | N/A | N/A | N/A |
6/30/2020 | 24,354 | 2,558 | 1,827 | 3,373 | N/A |
3/31/2020 | 24,248 | 2,781 | N/A | N/A | N/A |
12/31/2019 | 24,234 | 2,762 | 3,622 | 5,325 | N/A |
9/30/2019 | 24,479 | 9,101 | N/A | N/A | N/A |
6/30/2019 | 23,691 | 9,125 | 4,774 | 6,543 | N/A |
3/31/2019 | 22,444 | 9,132 | N/A | N/A | N/A |
12/31/2018 | 20,889 | 9,046 | 3,417 | 5,094 | N/A |
9/30/2018 | 19,103 | 2,567 | N/A | N/A | N/A |
6/30/2018 | 17,062 | 2,436 | 1,231 | 2,572 | N/A |
3/31/2018 | 15,609 | 2,363 | N/A | N/A | N/A |
12/31/2017 | 14,819 | 2,171 | 2,624 | 3,733 | N/A |
9/30/2017 | 14,491 | 2,115 | N/A | N/A | N/A |
6/30/2017 | 14,258 | 1,862 | N/A | 4,773 | N/A |
3/31/2017 | 13,899 | 1,789 | N/A | N/A | N/A |
12/31/2016 | 13,543 | 1,637 | N/A | 2,995 | N/A |
9/30/2016 | 13,271 | 1,674 | N/A | N/A | N/A |
6/30/2016 | 12,858 | 1,604 | N/A | 1,757 | N/A |
3/31/2016 | 12,507 | 1,575 | N/A | N/A | N/A |
12/31/2015 | 12,189 | 1,490 | N/A | 1,919 | N/A |
9/30/2015 | 12,030 | 1,432 | N/A | N/A | N/A |
6/30/2015 | 11,124 | 1,447 | N/A | 1,973 | N/A |
3/31/2015 | 10,552 | 1,263 | N/A | N/A | N/A |
12/31/2014 | 9,900 | 1,210 | N/A | 1,840 | N/A |
9/30/2014 | 9,205 | 1,074 | N/A | N/A | N/A |
6/30/2014 | 8,876 | 951 | N/A | 2,000 | N/A |
3/31/2014 | 8,434 | 886 | N/A | N/A | N/A |
12/31/2013 | 7,731 | 809 | N/A | 1,230 | N/A |
9/30/2013 | 8,069 | 868 | N/A | N/A | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: 1177's forecast earnings growth (13.7% per year) is above the savings rate (2.2%).
Earnings vs Market: 1177's earnings (13.7% per year) are forecast to grow faster than the Hong Kong market (11.3% per year).
High Growth Earnings: 1177's earnings are forecast to grow, but not significantly.
Revenue vs Market: 1177's revenue (6.9% per year) is forecast to grow slower than the Hong Kong market (7.4% per year).
High Growth Revenue: 1177's revenue (6.9% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: 1177's Return on Equity is forecast to be low in 3 years time (8.7%).